Oral antiviral agents for covid positive patients in primary care

East and North Hertfordshire NHS Trust

Mark Leamon (Pharmacist Manager – Clinical Services)

Krupa Mandalia (Pharmacist Manager – Medicine)

Wednesday 5th June 2024

ProudToBeENHT

Contents

East and North Hertfordshire NHS Trust

- Background to CMDU service (December 2021 to present)
- Current pathway for patients to obtain oral antivirals
- Where does Paxlovid® and molnupiravir fit in the treatment pathway
- Focus on Paxlovid®
- Focus on Molnupiravir
- Questions

Background to CMDU service

East and North Hertfordshire NHS Trust

- Covid Medicine Delivery Unit service
- National call to arms worked up and launched on 16th December 2021
- Specific aim – "*to reduce the severity of symptoms for clinically vulnerable patients in order to prevent hospital admission*"
- Service designed to reduce burden on secondary care so that only the most critically unwell covid patients were being admitted into hospital

Background to CMDU service

East and North Hertfordshire NHS Trust

- Three CMDU services set up within HWE ICB:
  - Lister Hospital, Stevenage
  - Princess Alexandra Hospital, Harlow
  - Watford General Hospital, Watford

- Similar set up:
  - Covid positive patients identified in community
  - Telephone triage with patient
  - Treatment decision made (if patient eligible)

Background to CMDU service

East and North Hertfordshire NHS Trust

- Treatment options:
  - Neutralising monoclonal antibody:
    - Sotrovimab
  - IV antiviral:
    - Remdesivir (initially licensed to treat ebola)
  - Oral antivirals:
    - Paxlovid®
    - Molnupiravir

Background to CMDU service

East and North Hertfordshire NHS Trust

- From 16th December 2021 to 31st March 2024:
  - >6,000 patients triaged
  - 2,590 patients treated (43%)
    - 865 treated with sotrovimab (33%)
    - 9 treated with remdesivir (0.3%)
    - 451 treated with Paxlovid® (17.4%)
    - 1,265 treated molnupiravir (48.8%)
- Pattern of referrals mirrored local and national prevalence data

Current pathway for oral antivirals

East and North Hertfordshire NHS Trust

- From 1st April 2024, access to anti-covid drugs for patients in primary care changed

- The 3 secondary care CMDUs were decommissioned and replaced by an ICB wide service primarily provided by HUC

- For the 1st time oral antivirals are available in community via FP10 prescriptions

Current pathway for oral antivirals

East and North Hertfordshire NHS Trust



Paxlovid® and molnupiravir in treatment pathways

East and North Hertfordshire NHS Trust

- Eligibility criteria is key to access for covid treatments
- National commissioning has changed multiple times over past 2.5 years
- Current latest guidance:
  - NICE TA 878
  - https://www.nice.org.uk/guidance/ta878

Paxlovid® and molnupiravir in treatment pathways

East and North Hertfordshire NHS Trust



Paxlovid® and molnupiravir in treatment pathways

East and North Hertfordshire NHS Trust

- High risk groups:
  - Down's syndrome and other genetic disorders
  - Solid cancer
  - Haematological diseases and haematological stem cell transplant (HSCT) recipients
  - Renal disease
  - Liver disease
  - Solid organ transplant recipients
  - Immune-mediated inflammatory disorders (IMID)
  - Respiratory disease
  - Immune deficiencies
  - HIV/AIDs
  - Neurological conditions

- Patients fitting into the criteria above – eligible for Paxlovid® or molnupiravir

Paxlovid® and molnupiravir in treatment pathways

East and North Hertfordshire NHS Trust

- Expanded cohort:
  - Aged 85 years and over
  - End-stage heart failure who have a long-term ventricular assistance device
  - Organ transplant waiting list
  - Aged 70 years and over, or who have a BMI of 35 kg/m^2 or more, diabetes or heart failure, and:
    - are resident in a care home, or
    - are already hospitalised

- Patients fitting into the criteria above – eligible for Paxlovid® only
- https://www.nice.org.uk/guidance/ta878/chapter/5-Supporting-information-on-risk-factors-for-progression-to-severe-COVID-19

Paxlovid® and molnupiravir in treatment pathways

East and North Hertfordshire NHS Trust



Paxlovid®

East and North Hertfordshire NHS Trust

- Combination product of two antiviral agents:
  - Nirmatrelvir 150mg tablets
  - Ritonavir 100mg tablets



- Efficacy: relative risk reduction of hospitalisation or death by 88% (started within 5 days of symptom onset)

Paxlovid®

East and North Hertfordshire NHS Trust

- Dose
  - Nil or mild renal impairment [CrCl ≥ 60ml/min]

    2 tablets of Nirmatrelvir (300mg) + 1 tablet of Ritonavir (100mg) TWICE daily

  - Moderate renal impairment (CKD stage 3) [CrCl 30-59mL/min]

    1 tablet of Nirmatrelvir (150mg) + 1 tablet of Ritonavir (100mg) TWICE daily

- Duration: 5 days

- Dispensing
  - Full dosing:
    - Supply ONE pack (30 tablets) of Paxlovid® 150 mg/100 mg film-coated tablets in the original box.
  - Reduced dosing:
    - Supply 10 x single-dose boxes (each containing ONE tablet of Nirmatrelvir 150mg and ONE tablet of Ritonavir 100mg)

Paxlovid®

East and North Hertfordshire NHS Trust

Sample prescription for FULL dosing (eGFR ≥ 60mL/minute)

East and North Hertfordshire NHS Trust

PATIENT PRESCRIPTION FORM

only be dispensed at the pharmacy within the hospital

Pharmacy use

Screened by | Labelled by | Dispensed by | Checked by | Given out by

Hospital number: Sample Prescription

Address: xxxxxx

Date of birth: xx/xx/xxxx

One patient pack will be supplied for drugs which are to continue. For short courses, state length of course.

Rx

Paxlovid®

Nirmatrelvir 150mg/Ritonavir 100mg tablets

Take TWO tablets of Nirmatrelvir and ONE tablet of Ritonavir

TWICE daily for 5 days

PO

Pharmacy quantity and strength endorsement

Drug allergies / sensitivities: NKDA

Pt. weight

Signature of prescriber | Print name: Dr ABC

Consultant team: Dr ABC

Paid / exempt

Affix stamp here

Bleep

Date: xx/xx/xx

ENH00196-5

Sample prescription for REDUCED dosing (eGFR 30-59mL/minute)

East and North Hertfordshire NHS Trust

PATIENT PRESCRIPTION FORM

only be dispensed at the pharmacy within the hospital

Pharmacy use

Screened by | Labelled by | Dispensed by | Checked by | Given out by

Hospital number: Sample Prescription

Address: xxxxxx

Date of birth: xx/xx/xxxx

One patient pack will be supplied for drugs which are to continue. For short courses, state length of course.

Rx

Paxlovid®
Nirmatrelvir 150mg/Ritonavir 100mg tablets

Take ONE tablet of Nirmatrelvir and ONE tablet of Ritonavir
TWICE daily for 5 days
PO

Note to pharmacy:
Please dispense in 10 x single-dose boxes & discard remaining Nirmatrelvir 150mg tablets not required

Pharmacy quantity and strength endorsement

Drug allergies / sensitivities: NKDA

Pt. weight

Signature of prescriber | Print name: Dr ABC

Consultant team: Dr ABC

Paid / exempt

Affix stamp here

Bleep

Date: xx/xx/xx

ENH00196-5

Paxlovid®

East and North Hertfordshire NHS Trust

- Cautions and special populations
- Renal impairment – contraindicated if CrCl < 30mL/minute
- Hepatic impairment- contraindicated in severe hepatic impairment (child-pugh class B)
- Pregnancy – Not recommended
- Breast feeding – Discontinue breast feeding during treatment and for 7 days after the last dose of Paxlovid®
- ADR – nausea, vomiting and diarrhoea
- Contraindications: Hypersensitivity to active substance or any of the excipients
- Drug interactions
  - Risk of serious adverse reactions!
  - Use the Liverpool COVID19 drug interaction checker for management of interactions
  - Examples of common drug interaction:
    - Statins - advice to hold statins for during treatment and for 3 days after the last dose of Paxlovid®
    - DOACs - Avoid
    - Amiodarone – Avoid

Paxlovid®

East and North Hertfordshire NHS Trust

- Liverpool covid drug interaction checker
- https://www.covid19-druginteractions.org/checker

- Example:



Molnupiravir

East and North Hertfordshire NHS Trust

- Single novel agent

- Efficacy: relative risk reduction of hospitalisation or death by 30% (started within 5 days of symptom onset)

Molnupiravir

East and North Hertfordshire NHS Trust

- Dose
  - 800mg (4 X 200mg) twice daily
- Duration
  - 5 days
- Dispensing: Supply ONE pack of 200 mg capsules (40 capsules pack-size) per prescription
- Cautions and special populations
  - Renal impairment: No dose adjustment is required
  - Hepatic impairment: No dose adjustment is required
  - Pregnancy: Not recommended
  - Breast feeding: Discontinue during treatment and for 4 days after the last dose Molnupiravir
  - ADR: nausea, vomiting, diarrhoea, dizziness
  - Contraindications: Hypersensitivity to active substance or any of the excipients
  - Drug interactions – no major drug interactions

Thank you

East and North Hertfordshire NHS Trust